Neoral 100mg Soft Capsules
*Company:
Novartis Ireland LimitedStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 18 July 2023
File name
Neoral capsules_REG PIL_PF23-0103_08.06.2023_clean_IPHA.pdf
Reasons for updating
- Change to section 6 - manufacturer
Updated on 20 June 2023
File name
Neoral 100mg caps_REG SPC_PF22-0134_08.06.2023_clean_IPHA.pdf
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 5.3 - Preclinical safety data
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 20 June 2023
File name
Neoral capsules_REG PIL_PF22-0134_08.06.2023_clean_IPHA.pdf
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 2 - driving and using machines
Updated on 11 January 2023
File name
Neoral 100mg caps_REG SPC_PF22-0183_09.01.2023_clean_IPHA.pdf
Reasons for updating
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 11 January 2023
File name
Neoral capsules_REG PIL_PF22-0183_09.01.2023_clean_IPHA.pdf
Reasons for updating
- Change to section 4 - possible side effects
Updated on 28 July 2022
File name
Neoral 100mg caps_REG SPC_PF22-0077_26.07.2022_clean_IPHA.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 28 July 2022
File name
Neoral capsules_REG PIL_PF22-0077_26.07.2022_clean_IPHA.pdf
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
Updated on 16 November 2021
File name
Neoral Soft Capsules_REG PIL_PF21-0206_10.11.2021_clean.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
Updated on 31 March 2021
File name
Neoral Soft Capsules_REG PIL_PF 20-0199_Clean.pdf
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 4 - possible side effects
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product contains
- Change to section 6 - what the product looks like and pack contents
Updated on 31 March 2021
File name
Neoral 100mg Caps REG SPC_PF 20-0199_March 2021_IPHA.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 6.3 - Shelf life
- Change to section 6.4 - Special precautions for storage
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 18 March 2020
File name
Neoral capsulesPF19-0254cleanIPHA.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - how to report a side effect
Updated on 18 March 2020
File name
Neoral 100mg Capsules REG SPC_PF19-0254 clean.pdf
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 23 December 2019
File name
Neoral REG PIL 46238043 PF XX-XXXX IPHA.pdf
Reasons for updating
- Improved presentation of PIL
Updated on 23 January 2019
File name
IPHA_Neoral SGC_46238043_IE_LFT_TBI 6 Jan 2019.pdf
Reasons for updating
- Change to section 6 - manufacturer
- Change to marketing authorisation holder
Updated on 09 August 2018
File name
Neoral 100mg Capsules REG SPC_PF18-0198-clean.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 24 September 2015
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 24 September 2015
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 04 March 2015
File name
PIL_8552_673.pdf
Reasons for updating
- New PIL for new product
Updated on 04 March 2015
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Pain of lower extremities
Isolated cases of pain of lower extremities have been reported in association with ciclosporin. Pain of lower extremities has also been noted as part of Calcineurin-Inhibitor Induced Pain Syndrome (CIPS).
Updated on 04 March 2015
Reasons for updating
- Change to side-effects
Updated on 29 September 2014
Reasons for updating
- Change to section 10 - Date of revision of the text
- Change due to harmonisation of SPC
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 17 September 2014
Reasons for updating
- Change due to harmonisation of PIL
Updated on 07 January 2013
Reasons for updating
- Change to warnings or special precautions for use
Updated on 26 November 2012
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.2 has been updated to include a paragraph about the conversion between oral ciclosporin formulations.
Section 4.4 and Section 4.8 have been updated to specifically describe PML and BK virus nephropathy in the general statement on infections in patients receiving immunosuppressive therapies.
Section 5.1 has been updated to include a sentence about the use of ciclosporin in liver transplant patients HCV+ and HCV-.
Updated on 07 September 2012
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 6.1 - List of excipients
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
- Correction of spelling/typing errors
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 09 December 2008
Reasons for updating
- Change to appearance of the medicine
- Change to date of revision
Updated on 04 December 2008
Reasons for updating
- Change to section 3 - Pharmaceutical form
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Updated on 17 April 2007
Reasons for updating
- Change to drug interactions
- Change to date of revision
- Correction of spelling/typing errors
Updated on 29 November 2006
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Section 4.1 - 4.6 and 5.1, 5.3 updated in order to align the National Prescribing Information with the Company Core Data Sheet.
Updated on 22 May 2006
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 17 May 2005
Reasons for updating
- Improved electronic presentation
Updated on 16 May 2005
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 26 August 2004
Reasons for updating
- New PIL for medicines.ie